ReNeuron Group plc Director declaration (5248K)

TIDMRENE

RNS Number : 5248K

ReNeuron Group plc

29 August 2023

ReNeuron Group plc

("ReNeuron" or the "Company")

Director declaration

ReNeuron Group plc (AIM: RENE) , a UK-based leader in Stem Cell and Exosome Technologies, has been notified by Barbara Staehelin, Non-Executive Director, that QvQ AG, a company of which she was Non-Executive Chair until 31 August 2022, entered liquidation in July 2023, within 12 months of her ceasing to be a director of that company.

This announcement is made in accordance with AIM Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies.

Contacts:

 
 
   ReNeuron                                                              www.reneuron.com/investors 
 Iain Ross, Executive Chairman                                                      Via Walbrook PR 
 John Hawkins, Chief Financial Officer 
 
 Allenby Capital Limited (Nominated 
  Adviser and Broker)                                                           [phone] 
 James Reeve/George Payne/Dan Dearden-Williams 
  (Corporate Finance) 
 Stefano Aquilino/Kelly Gardiner 
  (Sales & Corporate Broking) 
 
 Walbrook PR (Media & Investor Relations)            [phone] or [e-mail] 
 Paul McManus / Alice Woodings                                [phone] / [phone] 
                                                                                                654 
 
 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX(TM) platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNPPUWWRUPWGQA

(END) Dow Jones Newswires

August 29, 2023 02:00 ET (06:00 GMT)